BioCrossroads New Venture Competition Announces 2015 Call for Entries
The BioCrossroads New Venture Competition, an early stage business competition awarding more than $60,000 in prizes to life sciences and health information technology companies, is now accepting applications at www.biocrossroads.com. Since 2012, the competition has awarded more than $180,000 to twelve start-up companies which have been able to secure nearly $7 million in follow-on funding.
Early-stage biotechnology, pharmaceutical, medical device, diagnostic, ag-biotech, and health information technology companies developing innovative products and platforms are eligible to apply for the New Venture Competition. For consideration, companies must either be Indiana-based or be able to demonstrate a significant Indiana presence.
The winner receives a cash prize of $25,000 and receives access to the Indiana Seed Fund II staff and the fund’s network of resources to provide business planning and early-stage strategic support. They will also have the opportunity to make a presentation to the ISFII investment committee. The fund has invested in several of the previous winners, collectively totaling over $1 million.
The winner will be announced at the Indiana Life Sciences Summit Innovation Capital Day on October 14, 2015 and have an opportunity to pitch their business to the conference audience. Second and third place companies will be awarded cash prizes of $15,000 and $10,000 respectively. There will also be a Pre-Venture prize of $10,000 for a promising technology that is very early in its development.
Applications are available at www.biocrossroads.com and must be submitted by August 17, 2015. Companies invited to the next round will be notified by August 28 and must submit their pitch deck by September 11, 2015. Presentations will be held from September 14-18, 2015. The finalists will then present to a panel of expert judges before the Indiana Life Sciences Summit on Wednesday, Oct. 14.
Previous Winners include: Anagin, Dianotes, and Spensa Technologies.